Abstract:Background: Metabolic risk factors in primary biliary cholangitis (PBC) have not been well described in China. Additionally, it is unclear whether these factors have an impact on the prognosis of PBC patients. Therefore, this study aimed to investigate the prevalence of main metabolic risk factors in PBC, and to evaluate their prognostic values for liver-related outcomes. Methods: A cohort of 789 PBC patients was retrospectively studied between July 2008 and September 2019 by investigating the main metabolic risk factors and analyzing liver-related outcomes. Results: At presentation, 271 (34.3%) patients had concomitant hyperlipidemia, 126 (16.0%) had hypertension, 94 (11.9%) had type 2 diabetes mellitus (T2DM), and 17 (2.2%) had nonalcoholic fatty liver disease (NAFLD). Hyperlipidemia was found to be associated with the lower risk of liver-related death [ P <0.0001, hazard ratio (HR): 0.397, 95% confidence interval (CI): 0.268–0.588] and adverse outcomes ( P <0.0001, HR: 0.487, 95% CI:0.367–0.646), while hypertension was noted as a risk factor for liver-related death ( P =0.001, HR: 1.788, 95% CI:1.268–2.521) and adverse outcomes ( P =0.014, HR: 1.417, 95% CI:1.074–1.869). Moreover, age ≥ 55 years old ( P =0.005) and cirrhosis ( P <0.0001) had superimposition effects on hypertension as a risk factor for liver-related death, while only cirrhosis ( P <0.0001) had an effect on hypertension as a risk factor for adverse outcomes. Additionally, anti-sp100 was associated with adverse outcomes ( P =0.013) in PBC patients with hypertension in univariate Cox regression analysis. Conclusion: Hyperlipidemia, hypertension, and T2DM were found as main metabolic risk factors in PBC in China. Hyperlipidemia indicated a benign clinical outcome of PBC, while hypertension indicated a poor outcome of PBC. Older age and cirrhosis had superimposition effects on hypertension for liver-related poor outcomes. Anti-sp100 might be associated with adverse outcomes, especially in PBC patients with hypertension.

Factors associated with progression and outcomes of primary biliary cholangitis: A cohort study, 2010-2019

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

[Primary biliary cholangitis. Experience in 179 patients]

S2049 Predictors of Major Adverse Cardiovascular Events in Patients With Primary Biliary Cholangitis

Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value

Primary biliary cholangitis: opportunities and challenges

Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma

Clinical characteristics of patients with primary biliary cirrhosis

Clinical Characteristics of Primary Biliary Cirrhosis: a Retrospective Analysis of 101 Cases

Clinical and Pathology Analysis of Patients with Primary Biliary Cirrhosis

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

[Clinical and Pathological Characteristics of Primary Biliary Cirrhosis].

Long-term outcomes in patients with primary biliary cholangitis complicated with CREST syndrome

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

S2711 Primary Biliary Cholangitis: A Peculiar Presentation

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients